Madrigal Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Madrigal Pharmaceuticals
MDGL Stock  USD 441.68  15.83  3.72%   
Madrigal Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Madrigal Pharmaceuticals' valuation are provided below:
Gross Profit
902.3 M
Profit Margin
(0.30)
Market Capitalization
9.9 B
Enterprise Value Revenue
9.4528
Revenue
958.4 M
There are over one hundred nineteen available fundamental ratios for Madrigal Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to check Madrigal Pharmaceuticals' last-minute fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 13.7 B this year. Enterprise Value is expected to rise to about 13.9 B this year

Madrigal Pharmaceuticals Total Revenue

1.01 Billion

Check Madrigal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 23.4 M, Other Operating Expenses of 1.3 B or Research Development of 408 M, as well as many indicators such as Price To Sales Ratio of 12.95, Dividend Yield of 0.0073 or PTB Ratio of 22.76. Madrigal financial statements analysis is a perfect complement when working with Madrigal Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Madrigal Stock
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Madrigal Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.3 B1.3 B397.7 M
Slightly volatile
Total Stockholder Equity632.8 M602.7 M258.7 M
Slightly volatile
Common Stock Total Equity4.3 K2.3 K4.1 K
Slightly volatile
Common Stock Shares Outstanding23.6 M22.4 M11.2 M
Slightly volatile
Liabilities And Stockholders Equity1.3 B1.3 B397.7 M
Slightly volatile
Other Stockholder Equity2.8 B2.7 B965.7 M
Slightly volatile
Total Liabilities689.7 M656.9 M139 M
Slightly volatile
Common Stock2.9 K1.8 K4 K
Slightly volatile
Other Current Liabilities273.4 M260.4 M61 M
Slightly volatile
Total Current Liabilities325.8 M310.3 M80.4 M
Slightly volatile
Property Plant And Equipment Net6.8 M6.4 M2.2 M
Slightly volatile
Accounts Payable51.3 M48.9 M14.3 M
Slightly volatile
Cash208.6 M198.7 M94.1 M
Slightly volatile
Non Current Assets Total14.5 M13.8 M3.5 M
Slightly volatile
Non Currrent Assets Other719.9 K1.4 M800.8 K
Slightly volatile
Cash And Short Term Investments1 B983.6 M359.8 M
Slightly volatile
Short Term Investments824.1 M784.9 M267 M
Slightly volatile
Other Current Assets55.5 M52.9 M8.6 M
Slightly volatile
Property Plant And Equipment Gross2.2 M4.1 M1.8 M
Slightly volatile
Total Current Assets1.3 B1.2 B394.8 M
Slightly volatile
Short and Long Term Debt Total372.1 M354.4 M64.1 M
Slightly volatile
Short Term Debt967.1 K1 M5.1 M
Slightly volatile
Long Term Debt Total59.5 M56.7 M43.3 M
Slightly volatile
Capital Surpluse1.4 B1.3 B766.7 M
Slightly volatile
Capital Lease Obligations2.4 M2.3 M904.6 K
Slightly volatile
Short and Long Term Debt49.9 M55.9 M47.2 M
Slightly volatile
Net Invested Capital1.1 B1 B381.3 M
Slightly volatile
Net Working Capital1 B993.2 M379.1 M
Slightly volatile
Capital Stock1.6 K1.8 K2 K
Slightly volatile
Non Current Liabilities Other445.9 K445.1 K383.3 K
Slightly volatile

Madrigal Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses1.3 B1.3 B289.9 M
Slightly volatile
Research Development408 M388.5 M139.1 M
Slightly volatile
Total Operating Expenses1.3 B1.2 B278.7 M
Slightly volatile
Depreciation And Amortization2.5 M1.5 M3.4 M
Slightly volatile
Selling General Administrative525.3 M500.3 M106.3 M
Slightly volatile
Interest Income56.3 M53.7 M13.2 M
Slightly volatile
Non Operating Income Net Other4.1 M2.5 M2.2 M
Slightly volatile
Reconciled Depreciation1.3 M1.3 M374.9 K
Slightly volatile
Selling And Marketing Expenses86.4 M97.2 M106.1 M
Slightly volatile

Madrigal Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow72.4 M105 M72.8 M
Slightly volatile
Depreciation5 M4.7 M1 M
Slightly volatile
Other Non Cash Items6.8 M4.4 M6.5 M
Pretty Stable
Capital Expenditures716.7 K467 K478.9 K
Pretty Stable
Total Cash From Financing Activities153.5 M256 M185.3 M
Slightly volatile
End Period Cash Flow214 M203.8 M93.7 M
Slightly volatile
Stock Based Compensation103 M98.1 M28.7 M
Slightly volatile
Change Receivables6.3 K6.6 K20 K
Slightly volatile
Change To Netincome38.2 M36.4 M17.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.9513.631440.0998
Slightly volatile
Dividend Yield0.00730.00830.009
Slightly volatile
PTB Ratio22.7621.67689.5207
Slightly volatile
Days Sales Outstanding48.6551.2141227
Slightly volatile
Book Value Per Share49.0326.864640.1887
Pretty Stable
Average Payables472.1 K497 K857.8 K
Slightly volatile
Stock Based Compensation To Revenue0.09730.10240.8057
Slightly volatile
Capex To Depreciation0.09410.0991.9785
Very volatile
PB Ratio22.7621.67689.5207
Slightly volatile
EV To Sales13.113.793838.4703
Slightly volatile
Inventory Turnover0.380.75020.2279
Slightly volatile
Days Of Inventory On Hand4624871.8 K
Slightly volatile
Payables Turnover1.211.14870.3234
Pretty Stable
Sales General And Administrative To Revenue1.661.752.6373
Slightly volatile
Research And Ddevelopement To Revenue0.390.40542.4712
Slightly volatile
Capex To Revenue5.0E-45.0E-40.0463
Slightly volatile
Cash Per Share78.3143.841759.9935
Pretty Stable
Days Payables Outstanding302318212.4 K
Pretty Stable
Income Quality0.560.65750.7966
Slightly volatile
Intangibles To Total Assets0.00420.00590.0046
Pretty Stable
Current Ratio6.94.014910.1729
Very volatile
Tangible Book Value Per Share49.0126.535640.1551
Pretty Stable
Receivables Turnover6.777.12693.5833
Slightly volatile
Shareholders Equity Per Share49.0326.864640.1887
Pretty Stable
Debt To Equity0.620.5880.236
Very volatile
Capex Per Share0.01980.02080.1806
Slightly volatile
Revenue Per Share44.8642.720412.0809
Slightly volatile
Interest Debt Per Share8.7816.78997.0475
Pretty Stable
Debt To Assets0.30.28130.1181
Very volatile
Graham Number174196214
Slightly volatile
Operating Cycle5115381.9 K
Slightly volatile
Price Book Value Ratio22.7621.67689.5207
Slightly volatile
Days Of Payables Outstanding302318212.4 K
Pretty Stable
Ebt Per Ebit1.50.96062.2572
Pretty Stable
Effective Tax Rate0.260.30.3284
Slightly volatile
Company Equity Multiplier2.192.08991.5306
Very volatile
Total Debt To Capitalization0.240.37030.1445
Very volatile
Debt Equity Ratio0.620.5880.236
Very volatile
Quick Ratio6.893.773710.1462
Very volatile
Net Income Per E B T0.540.90.6826
Slightly volatile
Cash Ratio0.610.64043.4428
Slightly volatile
Days Of Inventory Outstanding4624871.8 K
Slightly volatile
Days Of Sales Outstanding48.6551.2141227
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00251.012
Pretty Stable
Price To Book Ratio22.7621.67689.5207
Slightly volatile
Fixed Asset Turnover15614948.2964
Slightly volatile
Debt Ratio0.30.28130.1181
Very volatile
Price Sales Ratio12.9513.631440.0998
Slightly volatile
Asset Turnover0.390.76090.2114
Slightly volatile
Price Fair Value22.7621.67689.5207
Slightly volatile

Madrigal Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.7 B13.1 B3.5 B
Slightly volatile
Enterprise Value13.9 B13.2 B3.5 B
Slightly volatile

Madrigal Fundamental Market Drivers

Forward Price Earnings666.6667
Cash And Short Term Investments983.6 M

Madrigal Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Madrigal Pharmaceuticals Financial Statements

Madrigal Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Madrigal Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-38.7 K-36.8 K
Total Revenue958.4 M1 B
Cost Of Revenue56.1 M59 M
Stock Based Compensation To Revenue 0.10  0.10 
Sales General And Administrative To Revenue 1.75  1.66 
Research And Ddevelopement To Revenue 0.41  0.39 
Revenue Per Share 42.72  44.86 
Ebit Per Revenue(0.31)(0.33)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
How To Invest In Madrigal
Details
Is Madrigal Stock a good investment?
Details
What is Madrigal Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(12.85)
Revenue Per Share
42.72
Quarterly Revenue Growth
2.108
Return On Assets
(0.16)
Return On Equity
(0.42)
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY